Focus: Ancora Heart is a early-stage medical device company focused on minimally invasive cardiac procedures for mitral valve regurgitation and heart failure, based in Santa Clara, CA. Founded in 2021, the company is pre-revenue and device-focused with a single lead platform (AccuCinch system).
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Ancora Heart presents a high-risk, high-impact early-stage device play best suited for operationally-minded professionals comfortable with startup uncertainty and focused on building a single differentiated cardiac platform.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ancora Heart
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ancora Heart's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo